173908-90-2

Upstream product

• 22316-50-3 1-phenyl 1,2,4,5-tetrahydro 2,4-dioxo 3H-1,5-benzodiazepine 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 161455-84-1 4-methoxy-N-(2-(phenylamino)phenyl)benzamide 
• 161455-85-2 N-(4-methoxybenzyl)-N-phenylbenzene-1,2-diamine 
• 100-07-2 4-methoxy-benzoyl chloride 
• 161455-86-3 1-(4-Methoxy-benzyl)-5-phenyl-3-(phenyl-hydrazono)-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 

Downstream Products

• 173908-74-2 [2-({2-[2,4-Dioxo-5-phenyl-3-(3-phenyl-ureido)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-acetyl}-phenyl-amino)-ethyl]-carbamic acid benzyl ester 
• 173908-72-0 ({2-[2,4-Dioxo-5-phenyl-3-(3-phenyl-ureido)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-acetyl}-phenyl-amino)-acetic acid ethyl ester 
• 173908-91-3 1-(2,4-dioxo-1-phenyl-2,3,4,5-tetrahydro-1H-benzo<1,4>diazepin-3-yl)-3-phenylurea 
• 153930-38-2 3-amino-1-phenyl-1,5-dihydrobenzo<1,4>diazepine-2,4-dione 

Relevant academic research and scientific papers

ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger"

Directed screening of compounds selected from the Glaxo registry file for contractile activity on the isolated guinea pig gallbladder (GPGB) identified a series of 1,5-benzodiazepines with peripheral cholecystokinin (CCK) receptor agonist activity. Agonis